The Josep Carreras Leukaemia Research Institute (IJC) is a comprehensive cancer research center dedicated to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of leukaemia and other hematologic malignancies, with the final aim of finding a cure for these diseases. It was created in 2010, and since then has experienced an exponential growth.
The IJC is also part of the network of Excellence Research Centers of Catalonia (CERCA) and was accredited as a Severo Ochoa Center of Excellence by the Ministry of Science, Innovation, and Universities in 2024. Since 2018, the Institute has also been accredited by the Scientific Foundation of the Spanish Association Against Cancer (FCAECC) Additionally, IJC is one of the centers integrated into the Institut de Recerca Germans Trias i Pujol (IGTP) accreditation as Accredited Health Research Institute (IIS) by the Carlos III Health Institute (ISCIII)
The IJC's main headquarters is located within the Can Ruti Biomedical Campus, alongside other leading biomedical institutions, providing direct access to cutting-edge scientific and technological facilities, as well as complementary community services. The IJC has six locations integrated into reference hospitals Hospital Germans Trias i Pujol, Hospital Clínic, Hospital Sant Pau, Hospital Josep Trueta, Hospital del Mar and Hospital San Joan de Déu. This facilitates close collaboration between basic and clinical researchers, fostering translational research that integrates basic science with clinical practice in clinical settings.
The Josep Carreras Leukemia Research Institute is looking for a Head of the Proteomics Platform
RESEARCH DESCRIPTION
Our Proteomics Unit is at the forefront of applying precision medicine to leukaemia through various OMICS approaches, offering mass spectrometry services to both the academic and private sectors. We specialize in cutting-edge proteomic methodologies that redefine how we perceive, manage, and prevent disease, optimizing analyses of clinical samples.
We are looking for a highly motivated and experienced Head of the Proteomics Platform to lead Proteomics Unit in managing and executing a personalized medicine project.
MAIN RESPONSABILITIES
• Design and execute LC-MS-based proteomic analyses.
• Supervise sample preparation, LC-MS operations and maintenance, data analysis, and laboratory general maintenance.
• Optimize and create new protocols to be at the state-of-the-art in proteomics.
• Collaborate with internal and external researchers to design experiments and optimize protocols.
• Train users in proteomic techniques.
• Contribute to research papers, presentations, and posters.
WHAT WE NEED
• PhD in Biology, Biochemistry, Molecular Biology, or a related field.
• Proficiency in chromatography, LC-MS, and data analysis.
• Minimum 5 years of experience with high-end mass spectrometers, including Orbitrap-based instruments and nano-HPLC and micro-HPLC systems.
• Experience in proteomics research (sample prep, LC-MS, data analysis)
• Minimum 5 years of experience in biomedical research.
• Minimum 2 years of team leadership and management experience as an area supervisor or similar.
• Strong leadership, teamworking, and interpersonal skills
• Ability to work independently and manage multiple projects simultaneously.
• Fluent in English with excellent communication skills.
WHAT WE OFFER
• Immediate incorporation.
• Permanent contract (Taxa de reposició 2025)
• Full-time position (39h per week).
• Measures to reconcile work and family life (flexible work schedule, teleworking, 23 working days of vacation, and 12 days for personal matters in 2026).
• Flexible remuneration program (kindergarten and other measures).
• Training opportunities.
• Join a highly collaborative team and engage in exciting projects.
• Work within a dynamic environment blending basic and clinical research.
• Enjoy the vibrant surroundings of the Barcelona metropolitan area, IJC headquarters located in nature.
DEADLINE
Please submit your application by 17/06/2026.
WHO WE ARE?
The mission of the Josep Carreras Leukaemia Research Institute is to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of cancer, with a special emphasis on Leukaemia and other malignant blood diseases, with the aim of finding a cure for these diseases.
The IJC’s vision is to be a world-class reference and excellent research center that contributes to the improvement of results, and the cure of patients affected by leukaemia and other malignant haemopathies, through innovation, sustainability, social responsibility, talent, and professional experience.
In 2019, IJC was honored with the “Human Resources Excellence in Research Award” by the European Commission, recognizing the alignment of our human resources policies with the European Charter for Researchers and Code of Conduct for the Recruitment of Researchers. The Human Resources Strategy for Researchers (HRS4R) guides research centers of excellence in implementing and upholding these standards within their policies, emphasizing training, professional development, and mobility opportunities.
The IJC’s commitment to these values and principles strengthens our internal policies and ensures that our members have the optimal conditions and environment for their professional development.
The Board of Trustees is composed of representatives of the Generalitat de Catalunya (regional government), University of Barcelona, Autonomous University of Barcelona, the City of Badalona and the Jose Carreras International Leukaemia Foundation
The Catalan government provides hard money on an annual basis. The Jose Carreras International Leukaemia Foundation provides start-up funds, project funds as well as financial support for investments.
The JCI has an international scientific advisory board served by prominent researchers from US and Europe.
The IJC has been awarded ERC and other EU grants.
The IJC is an equal-opportunity employer. We evaluate qualified applicants without regard to race, color, religion, sex, national origin, disability, or other legally protected characteristics.
The Josep Carreras Leukaemia Research Institute was founded in 2010, by the Josep Carreras Foundation and the Government of Catalonia, as the first European research centre devoted exclusively to leukaemia and other malignant blood diseases, and one of the few that exist in the world.
We investigate basic, epidemiological, preventive, clinical, and translational aspects of leukaemia and other hematologic malignancies.
Our research aims to identify new therapeutic targets and enable us to develop more precise and less aggressive treatments. We aspire to understand the origin and development of leukaemias and other malignant haematological pathologies, to be able to prevent them.
We work for a future in which all leukaemias will be curable. Our fight will endure until there's a cure.
